3rd Annual Neuromuscular Drug Development Summit

Memo

The 3rd Neuromuscular Drug Development Summit presents a unique opportunity to: - Uncover the right outcome measures to use in your clinical trial and discover how to establish clinical meaningfulness with Biogen - Hear approaches to optimizing therapeutic efficacy in SMA, an innovative approach to trial design for real world SMA population and how combinatorial treatments may improve SMA treatment outcomes with Roche, PTC Therapeutics and John Hopkins University School of Medicine - Assess emerging neurophysiological methods for more quantitative, faster readouts and the need to explore digital capture tools to improve therapeutic R and D with Harvard Medical School and the Parent Project Muscular Dystrophy (PPMD) - Dissect various dosing strategies and discuss how to demonstrate a clear mechanistic route between dose, mechanisms of action and endpoints with NMD Pharma and Argenx - Evaluate the role of biomarkers, how regulatory agencies approach the integration of biomarkers in clinical trials and biomarker outcome measures outside dystrophin with ReveraGen Biopharma and the Critical Path Institute - Hear how Avidity Biosciences are developing an oligonucleotide antibody conjugate for the treatment of DM1 Uniting drug developers and academics from all corners of the world, the virtual Neuromuscular Drug Development Summit is your opportunity to discuss recent advances in this fast-evolving field, convey lessons learned and network to build long lasting partnerships. URLs:Tickets: https://go.evvnt.com/673668-0?pid=5569 Brochure: https://go.evvnt.com/673668-3?pid=5569  Date and Time: On Tuesday December 01, 2020 at 8:30 am ends Thursday December 03, 2020 at 4:00 pm Prices:Conference Only Admission - Industry Attendees: USD 1899.00,Conference + 1 Workshop - Industry Attendees: USD 2298.00,Conference + 2 Workshops - Industry Attendees: USD 2697.00 Speakers: Katherine Meilleur, Principal Clinical Scientist Neuromuscular Development Unit, Biogen, Eric Hoffman, Associate Dean of Research/Co-Founder and VP, ReveraGen Biopharma SUNY Binghamton School of Pharmacy, Terry Partridge, Professor of Integrative systematic Biology Children's National Medical Center and George Washington University, Josie Godfrey, Strategic Director Project HERCULES, Pat Furlong, Founding President and CEO Parent Project Muscular Dystrophy (PPMD), Eva Chin, Chief Development Officer NMD Pharma, Stojan Peric ,Assistant Professor, Neurologist, Neurology Clinic, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Serbia, Nikolai Naryshkin, Vice President External Research and Alliance Management, Translational Medicine, PTC Therapeutics, Inc, Maria Judit Molnarm , Professor of Neurology, Psychiatry and Clinical Genetics, Director of the Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Jodi Wolff, Head of Patient Advocacy Santhera Pharmaceuticals, Charlotte J. Sumner,Professor of Neurology, Neuroscience Johns Hopkins University School of Medicine, Jane Larkindale , Executive Director, Duchenne Regulatory Science Consortium Executive Director, Rare Disease Cures Accelerator- Data and Analytics Platform, Kathyrn Wagner, Director of the Center for Genetic Muscle Disorders, Kennedy Krieger Institute, Professor of Neurology and Neuroscience, Johns Hopkins School of Medicine, Ranjan Batra, Vice President of Research and Development Locana, Andrew A Wolff , Senior Fellow, Clinical Research and Development Cytokinetics, Mark Diamond , Managing Director and CEO Antisense Therapeutics, Art Levin, CSO Avidity Biosciences, Seward Rutkove, Professor of Neurology and Chief of the Division of Neuromuscular Disease Harvard Medical School/Beth Israel Deaconess Medical Center, Peter Ulrichts ,Scientific Lead Neuromuscular Franchise Argenx, Paulo Fontoura , Global Head and SVP, Neuroscience and Rare Diseases Clinical Development Roche, Kristina Sjöblom, Nygren CMO, Head of Development Santhera Pharmaceuticals